Oncodesign, Sanofi ink research collaboration and license agreement

Friday, September 14, 2012 11:57 AM

Oncodesign, a French drug discovery company and oncology pharmacology service provider, has entered into a strategic research collaboration with global healthcare company Sanofi to apply Oncodesign's Nanocyclix technology to Sanofi kinase target programs.

Oncodesign will exclusively apply its Nanocyclix technology platform in multiple undisclosed Sanofi kinase programs for a number of therapeutic applications over a period of four years. Oncodesign is entitled to a technology access fee and discovery, development, regulatory and commercial milestone payments totaling up to $170 million and low single digit royalties on net sales.

The application of Nanocyclix to Sanofi's kinase lead programs aims to allow for a quicker selection of development candidates for multiple undisclosed kinase targets in kinase families that are notoriously difficult to address.

Nanocyclix is a proprietary medicinal chemistry technology and research platform based on macrocyclisation chemical methodology and knowledge that gives access to potent and selective kinase inhibitors based on shape complementarity in the ATP binding site of kinases. In this way, unprecedented selectivity is achieved even among kinases with high homology. In addition, the technology allows rapid improvement in the pharmacokinetic properties of the Nanocyclix leads based on established knowledge.

"This new agreement illustrates the leading position of Oncodesign in the kinase inhibitor field. Our Nanocyclix technology is now clearly established as a high value, differentiating approach that gives access to next generation kinase inhibitors in multiple therapeutic indications," said Jan Hoflack, Ph.D., CSO of Oncodesign.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

July 21

As job growth in drug development sector soars, more employees are seeking new opportunities

U.K. study: Prisoners should have the right to participatein clinical trials on moral grounds, for healthcare access

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

July

IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

June

CRO market poised for growth and consolidation
Sponsors expanding pipelines, shrinking infrastructure fuel strategic outsourcing

Strategies for success evolving in phase I space
Sites see increasing complexity, more patients, greater focus on efficacy

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs